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Abstract
Dyslipidemia, and inflammatory markers: high-sensitivity C-reactive protein (hs-CRP),
myeloperoxidase (MPO), lipoprotein associated phospholipase A2(Lp-PLA2), and lipid peroxides
(LP) are insufficient to predict the onset, extent, and prognosis of CHD. Lipoxins (LXs), resolvins,
and protectins are derived from ω-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), and ω-6 arachidonic acid in the presence of aspirin; whereas nitrolipids are formed due
to the interaction between polyunsaturated fatty acids and nitric oxide (NO). LXs, resolvins,
protectins, and nitrolipids are endogenous anti-inflammatory lipid molecules that inhibit production
of interleukin-6 (IL-6) and tumor necrosis factor- α (TNF-α), suppress free radical generation,
enhance NO generation; and accelerate tissue repair. Thus, beneficial actions of EPA/DHA and
aspirin in CHD could be attributed to the formation of LXs, resolvins, protectins, and nitrolipids
and suggest that their plasma levels aid in the prediction and prognosis of CHD.
Introduction
An increase in the plasma concentrations of high-sensitive
C-reactive protein (hs-CRP), tumor necrosis factor-α
(TNF-α), and interleukin-6 (IL-6) occurs in coronary heart
disease (CHD) suggesting that it is a low-grade systemic
inflammatory condition [1]. Myeloperoxidase (MPO), an
abundant leukocyte enzyme, and lipoprotein-associated
phospholipase A2 (Lp-PLA2), produced by macrophages,
independently predict the early risk of adverse cardiac
events [2,3]. Despite these advances, it is not clear which
of these indices are better suited to predict CHD, its sever-
ity, and consequent complications.
Although, dyslipidemia, diabetes mellitus, hypertension,
and obesity are important risk factors for CHD, there are
a significant number of subjects who develop CHD with-
out these risk factors. We and others observed that in
CHD, hypertension, diabetes mellitus, hyperlipidemias,
and obesity, EFA (essential fatty acid) metabolism is
abnormal such that plasma phospholipid concentrations
of arachidonic acid (AA), eicosapentaenoic acid (EPA),
and docosahexaenoic acid (DHA) are low [4-11]. Despite
the fact that deficiency of polyunsaturated fatty acids
(PUFAs) is present in CHD, hypertension, diabetes,
hyperlipidemias, and obesity and increased intake of
PUFAs are of benefit in these diseases [4,7,9-11], exact
mechanism(s) of their protective action remained unex-
plained.
Metabolism of essential fatty acids and its relevance to 
CHD
Essential fatty acids (EFAs) are important constituents of
all cell membranes including endothelial and myocardial
cells and determine and influence the behaviour of mem-
brane-bound enzymes and receptors by altering mem-
brane fluidity. EFAs are essential, not synthesized in the
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body; and hence, have to be obtained in diet [4]. The two
EFAs are ω-6 cis-linoleic acid (LA, 18:2) and the ω-3 α-
linolenic acid (ALA, 18:3). AA formed from LA is the pre-
cursor of 2 series of PGs, thromboxanes (TXs) and 4 series
of leukotrienes (LTs); whereas ALA is converted to EPA
that gives rise to 3 series of PGs, TXs and 5 series LTs (see
Figure 1). LA, γ-linolenic acid (GLA), dihomo-GLA
(DGLA), AA, ALA, EPA and docosahexaenoic acid (DHA,
22:6, ω-3) are all PUFAs, but only LA and ALA are EFAs.
AA and EPA and their respective PGs, TXs, and LTs play a
significant role in atherosclerosis, CHD, bronchial
asthma, inflammatory bowel disease, and other inflam-
matory conditions [4].
AA, EPA, and DHA give rise to LXs, resolvins, and pro-
tectins. Aspirin converts AA, EPA and DHA to form aspi-
rin-triggered 15 epimer LXs (ATLs) that inhibit local
inflammation on the vessel wall by regulating the motility
of leukocytes, eosinophils, and monocytes [4,12-14].
COX-2 enzyme is essential for the formation of LXs,
Scheme showing the metabolism of essential fatty acids Figure 1
Scheme showing the metabolism of essential fatty acids. Red line indicates initiation and/or progression of disease. Green line 
indicates protection from disease and better prognosis. Double arrow indicates feedback regulation that could be both positive 
and negative. Leukocytes, macrophages, lymphocytes, and myocardial cells produce various PGs, LTs, TXs, cytokines, MPO, 
and other pro-inflammatory molecules that participate in the pathogenesis of CHD. Leukocytes, macrophages, lymphocytes, 
myocardial cells also produce lipoxins, resolvins, NPD1, and nitrolipids that have cardioprotective action and enhance healing 
and prevent or arrest atherosclerosis. Hence, measuring these cardiotoxic and cardioprotective molecules may help in the pre-
diction and prognosis of CHD, and response to therapy.Lipids in Health and Disease 2008, 7:19 http://www.lipidworld.com/content/7/1/19
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whose deficiency leads to an interaction between leuko-
cytes (PMNs) and endothelial cells that result in endothe-
lial damage, initiation and progression of atherosclerosis,
thrombus formation and CHD.
EPA can be converted to 18R-HEPE (18R- hydroxy-eicos-
apentaenoic acid), 18-HEPE, and 15R-HEPE. Activated
human PMNs, in turn, convert 18R-HEPE to 5,12,18R-tri-
HEPE and 15R-HEPE to 15-epi-LXA5 by 5-lipoxygenase.
Both 18R-HEPE and 5,12,18R-triHEPE inhibited LTB4-
stimulated PMN transendothelial migration similar to 15-
epiLXA4. 5,12,18R-triHEPE competed with LTB4 for its
receptors and inhibited PMN infiltration, and thus,
5,12,18R-triHEPE suppresses LT-mediated responses
when present at the sites of inflammation [4,12-15].
Similarly, DHA is transformed enzymatically to 17R series
of hydroxy DHAs (HDHAs) that, in turn, is converted by
PMNs to di- and tri-hydroxy containing docosanoids
[4,16]. Similar small molecular weight compounds (sim-
ilar to HDHAs) are generated from AA and EPA. Thus,
15R-hydroxy containing compounds are formed from AA,
18R series from EPA, and 17R-hydroxy series from DHA
that have potent anti-inflammatory actions and induce
resolution of the inflammatory process and are called
"resolvins" (see Figure 1). Resolvins inhibited cytokine
generation, leukocyte recruitment, leukocyte diapedesis,
and exudate formation. AA, EPA, and DHA-derived
resolvins inhibited brain ischemia-reperfusion injury.
10,17S-dihydroxydocosatriene derived from DHA termed
as neuroprotectin D1 (NPD1) reduced infiltration of
PMNs, showed anti-inflammatory and neuroprotective
properties [4,17], and inhibited oxidative stress-induced
apoptosis of human retinal pigment epithelial cells [18].
Both LXs and NPD1 enhanced wound healing [19], and
promoted brain cell survival [20,21]. Thus, lipoxins,
resolvins, and protectins derived from AA, EPA, and DHA
have cardio-protective, neuroprotective, and other cyto-
protective actions. It is noteworthy that leukocytes, mac-
rophages, endothelial cells, and myocardial cells have the
complete enzyme system for the conversion of PUFAs to
PGs, TXs, LTs, LXs, resolvins, protectins and nitrolipids.
Based on these findings, I propose that failure to produce
adequate amounts of LXs, resolvins, NPD1 (and other
protectins), and nitrolipids or interference with their
action could lead to initiation and persistence of inflam-
mation and tissue damage including CHD.
Nitrolipids and CHD
NO reacts with PUFAs to yield their respective nitroalkene
derivatives, termed as nitrolipids, produce vascular relax-
ation, inhibit neutrophil degranulation and superoxide
formation, and inhibit platelet activation [22-24]. Nitrol-
ipids have endogenous PPAR-γ ligand activity and release
NO [24]. Thus, nitrolipids prevent platelet aggregation,
thrombus formation, atherosclerosis, and suppress
inflammation. Thus PUFAs not only form precursors to
various eicosanoids, resolvins, LXs, and NPD1 but also
react with NO to form nitrolipids that prevent platelet
aggregation and thrombus formation and hence, arrest of
atherosclerosis. Nitrolipids also have anti-inflammatory
actions, and so, their deficiency can cause CHD.
Pro- and anti-inflammatory molecules in CHD
Coronary heart disease (CHD) is a low-grade systemic
inflammatory condition since these subjects have
enhanced plasma levels of reactive oxygen species (ROS),
CRP, IL-6, and TNF-α and low circulating levels of NO
and various PUFAs [1-6]. Increased ROS decreases anti-
oxidant content of the cells/tissues. This leads to an imbal-
ance between the pro- and anti-oxidant molecules that
favor tissue damage in CHD [25]. Hs-CRP, LP-LPA2, ROS,
and MPO have cytotoxic actions, whereas LXs, resolvins,
protectins, and nitrolipids show cytoprotective and cardi-
oprotective actions, in view of their ability to inhibit pro-
duction of IL-6 and TNF-α, suppress free radical
generation, and enhance tissue repair [4,12-24,26-28].
Hence, an increase in hs-CRP, LP-LPA2, ROS, and MPO
and a decrease in LXs, resolvins, protectins, and nitrolip-
ids or both not only predisposes to CHD but also indi-
cates poor prognosis. When EPA, DHA, AA, and aspirin
are given together in adequate amounts, LXs, resolvins,
protectins, and nitrolipids are formed that prevent myo-
cardial damage. This explains the beneficial actions of
EPA/DHA/AA and aspirin in both primary and secondary
prevention of CHD [4,26-28].
This implies that deficiency of PUFAs seen in CHD and
other conditions leads to reduced formation of NO, LXs,
resolvins, protectins, and nitrolipids that would initiate
atherosclerosis and CHD and/or worsen an existing dis-
ease. It is predicted that plasma levels of hs-CRP, ROS,
MPO, Lp-PLA2 and LP will be increased whereas those of
LXs, resolvins, NPD1 and nitrolipids will be decreased in
patients with CHD. Furthermore, a balance between these
pro- and anti-inflammatory molecules may aid in predict-
ing prognosis of CHD. For instance, subjects with low lev-
els of LXs, resolvins, NPD1, and nitrolipids may have poor
outcome and have higher incidence of cardiac failure,
arrhythmias, and recurrence of myocardial infarction.
Statins and thiazolidinediones enhance the formation of
myocardial 15-epi-LXA4 and EFAs mediate some of their
actions that could explain the ability of statins and glita-
zones to prevent CHD [29-31]. This implies that those
who have low levels of EFAs and their metabolites could
be resistant to the beneficial action of statins and glita-
zones; and such subjects will be benefited from supple-
mentation of AA/EPA/DHA.Lipids in Health and Disease 2008, 7:19 http://www.lipidworld.com/content/7/1/19
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Hypothesis: EFAs/PUFAs and their metabolites are low in 
CHD
One of the risk factors for CHD is elevated levels of homo-
cysteine. Southeast Asians especially, Indians (people
from Indian subcontinent) are at high risk of CHD [32].
The increased incidence of CHD in Indians has been
attributed to their proatherogenic diet, lack of exercise,
smoking, high levels of homocysteine and LP(a) lipopro-
tein, endothelial dysfunction and enhanced plaque and
low-grade systemic inflammation [32]. They also have
increased prevalence of metabolic syndrome X including
insulin resistance, hypertension, abdominal obesity, and
dyslipidemia, and type 2 diabetes mellitus, factors that
could explain the high incidence of CHD. These factors
coupled with the observation that only limited number of
patients with CHD receive thrombolytic therapy (36.8%),
antiplatelet drugs (~98%), β-blockers (59.3%), lipid-low-
ering drugs (52%), ACE inhibitors/angiotensin-II receptor
blockers (56.8%), anticoagulants (81.3%), percutaneous
coronary intervention (7.5%), coronary artery bypass
graft (2.9%) and that the incidence of death and compli-
cations are more common in Indians [32,33] suggests that
as a race Indians are the most vulnerable population for
cardiovascular diseases. It is estimated that by 2010, 60%
of the world's heart disease is expected to occur in India
[34] and are likely to suffer from CHD at an earlier age
than do people in developed countries [35]. Unfortu-
nately, all the studies performed in Indians, residing both
in India and the developed countries; concentrated on the
incidence of the disease and the prevalence of risk factors
but none have looked at the pathophysiology of the dis-
ease. In a previous study, I showed that even healthy Indi-
ans have lower concentrations of various PUFAs
compared to Canadians and Americans (USA) [36]. This
suggests that as a race Indians have low activity of Δ6 and
Δ5 desaturases that is responsible for decreased concentra-
tions of various PUFAs in their plasma and tissues as a
result of which the formation of PGE1, PGI2, PGI3, lipox-
ins, resolvins and protectins will be low that may render
them more susceptible to develop low-grade systemic
inflammatory conditions including CHD [36-41]. This is
further supported by the observation that Indians and
Europeans with CHD have low levels of PUFAs in their
plasma phospholipid fraction [6,37,38]. Furthermore,
low activity of Δ6 and Δ5 desaturases could lead to the ini-
tiation and progression of insulin resistance and athero-
sclerosis in Indians as previously proposed [42,43]. These
evidences suggest that Indians are at high risk of develop-
ing CHD and its associated death and complications
[32,33] partly due to a defect in the activity of Δ6 and Δ5
desaturases that result in low plasma and tissue concentra-
tions of PUFAs and their products: PGE1, PGI2, PGI3,
lipoxins, resolvins, protectins, and nitrolipids [36-41].
PUFAs and their products prevent platelet aggregation,
lower blood pressure, reduce LDL-C, ameliorate the
adverse actions of homocysteine, inhibit ACE (angi-
otensin converting enzyme) and HMG-CoA enzyme activ-
ities and thus, may function as endogenous "polypill"
[44]. These evidences suggest that PUFAs of both ω-3 and
ω-6 series can be given to high risk subjects to prevent
CHD and other cardiovascular diseases [44]. It is likely
that subjects with low levels of various PUFAs and their
products: PGE1, PGI2, PGI3, lipoxins, resolvins, protectins,
and nitrolipids are not only vulnerable to develop CHD
but also have poor outcome and higher incidence of car-
diac failure, arrhythmias, and recurrence of myocardial
infarction (Figure 1) since these endogenous lipid mole-
cules have anti-arrhythmic action, enhance wound heal-
ing and suppress inflammation [45-49], though some
studies disputed the anti-arrhythmic action of PUFAs
[50,51]. In this context, it is interesting to note that folic
acid not only reduces plasma homocysteine levels but
also augments the metabolism of essential fatty acids such
that plasma and tissue levels of various PUFAs are
enhanced (reviewed in [44,52-55]). It is possible that
some subjects may have normal concentrations of EFAs/
PUFAs in their plasma and tissues but the formation of
lipoxins, resolvins, protectins, and nitrolipids may be
defective. Recently it was noted that the gene that encodes
the 5-lipoxygenase activating protein (FLAP) and its risk
variant results in an almost 2-fold increased risk of CHD
by leading to the production of leukotriene B4 (LTB4), a
potent chemokine mediators of arterial inflammation
[56-58]. This is supported by the observation that patients
with CHD produce more LTB4 than controls, suggesting
that LTB pathway is upregulated in CHD [56]. It is inter-
esting to note that lipoxins are potent inhibitors of LTB4
and leukotrienes [59].
Thus, it is proposed that subjects at high risk for CHD
have increased hs-CRP, MPO, Lp-PLA2, LP, IL-6, TNF-α,
LTB4 and low levels of various PUFAs, LXs, resolvins, pro-
tectins, and nitrolipids, and the balance between these
pro-inflammatory and anti-inflammatory molecules may
also aid in the prediction and prognosis of CHD.
If this proposal is true, it implies that PUFAs are not only
useful in the prevention of CHD but development of sta-
ble and synthetic analogues of LXs, resolvins, NPD1, and
nitrolipids may form a new approach in the management
of cardiovascular diseases.
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